BJDXHealthcare · Medical DevicesBJDX Stock Forecast: Bluejay Diagnostics, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 1 Aug 2026 — in the weakest quartile.
BJDX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Bluejay Diagnostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (100): Smaller than most of the companies we track.
Value (5): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Bluejay Diagnostics, Inc. — and when they’d sell — is the membership.
BJDX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BJDX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Aug 2023 | Dawson James | Downgrade | Neutral | — |
| 12 Jan 2022 | Dawson James | Initiates | Buy | $10 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BJDX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Bluejay Diagnostics, Inc. (BJDX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.0×
- Price / sales
- —
- Price / book
- 0.2×
- EV / EBITDA
- 0.4×
Cheaper than 74% of US stocks
Cheaper than 89% of US stocks
Cheaper than 59% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −171.6%
- Return on assets
- −79.6%
- Dividend yield
- —
Higher than 8% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
BJDX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BJDX appears on the weeks it earns a place.
Frequently asked questions about BJDX stock
How does Ticker Nerd's model rank BJDX?
As at 1 Aug 2026, Bluejay Diagnostics, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (100 of 100).
What is the BJDX stock forecast for 2030?
No analyst covering Bluejay Diagnostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BJDX are extrapolating price history, which says nothing about the business.
How has BJDX stock performed over the past year?
Bluejay Diagnostics, Inc. returned -84.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Bluejay Diagnostics, Inc. do?
Bluejay Diagnostics Inc. is a medical technology company focused on developing and marketing rapid diagnostic solutions for use in clinical settings.
About Bluejay Diagnostics, Inc.
Bluejay Diagnostics Inc. is a medical technology company focused on developing and marketing rapid diagnostic solutions for use in clinical settings. The company specializes in minimally invasive point-of-care tests and devices designed to provide timely, lab-quality biomarker results near the patient, supporting faster clinical decision-making in critical care environments. Its flagship Symphony platform is a near-patient biomarker detection system aimed at conditions where early and precise measurement of inflammatory and infectious markers can guide treatment. Bluejay Diagnostics primarily targets the infectious disease, inflammation, and oncology markets, working to enable more efficient triage and monitoring of patients in emergency departments, intensive care units, and other acute-care settings. Headquartered in Acton, Massachusetts and founded in 2015, the company operates within the health technology sector and the medical specialties industry, serving healthcare providers seeking to streamline workflows and improve access to actionable diagnostic information at or near the point of care.
CEO Mr. Indranil Dey · 6 employees · United States · https://bluejaydx.com